Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 11Lymphoma, B-Cell, Marginal Zone 7Hematologic Diseases 7Waldenstrom Macroglobulinemia 6Lymphoma 4Leukemia, B-Cell 4Lymphoma, Follicular 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphoid 2Leukemia 2Syndrome 1Multiple Myeloma 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 260fludarabine phosphate 163Methotrexate 124Rituximab 112Cytarabine 109Filgrastim 106fludarabine 92Busulfan 86Peripheral Blood Stem Cell Transplantation 83Etoposide 82Vincristine 80Radiotherapy 79Tacrolimus 73Mycophenolic Acid 72Antilymphocyte Serum 68Whole-Body Irradiation 66Melphalan 63Dexamethasone 63Cyclosporine 58Doxorubicin 51Prednisone 44Methylprednisolone 44Alemtuzumab 44Mercaptopurine 41Granulocyte Colony-Stimulating Factor 40pegaspargase 35Daunorubicin 34Clofarabine 33Thiotepa 31Asparaginase 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × pirtobrutinib × Lymphoid × Clear all
NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06812715 2025-08-06

PIPOZA

Peter MacCallum Cancer Centre, Australia

Phase 2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡